Clinical and Renal Biopsy Findings Predicting Outcome in Renal Thrombotic Microangiopathy: A Large Cohort Study from a Single Institute in China

Table 2

Treatment of patients with thrombotic microangiopathy.

Etiologies or associated disorders; (109 patients in total)	Treatment
	PI/PE	CS	Cytotoxic agents	ACEI/ARB
D + HUS ()	0	0	0	1
aHUS ()	4	6	3 (CYC)	5
MHT ()	0	10	6 (CYC or MMF)	40
Pregnancy associated
Preeclampsia/HELLP ()	2	2	0	3
HUS ()	5	6	2 (CYC)	4
Others
Connective tissue disorders ()	4	17	12 (CYC or LEF)	10
HSCT ()	0	2	1 (CsA)	0
Castleman’s disease ()	0	3	2 (chemotherapy)	1
Cryoglobulinemia ()	0	1	1 (LEF)	1
Glomerulopathy ()	0	1	1 (CYC)	1

Notes: D + HUS: diarrhea positive hemolytic uremic syndrome; aHUS: atypical hemolytic uremic syndrome; MHT: malignant hypertension; HELLP: hemolysis, elevated live enzymes, low platelet count; HSCT: hematopoietic stem cell transplantation; PI: plasma infusion; PE: plasma exchange; CS: corticosteroid; ACEI: angiotensin-converting enzyme inhibitors; ARB: angiotensin II receptor blockers; CYC: cyclophosphamide; MMF: mycophenolate mofetil; LEF: leflunomide; CsA: cyclosporine A.